Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

slcimmuno,

¨Anyway - Lots of oppty in OM for multiple treatments, lots of patients in need, with oral rinse mode of admin likely a large Adv¨

I agree. But I refer to ipix pr of 3/15/18 where, near the bottom, ipix states:

¨While already competitively advantaged as an oral rinse versus IV drug delivery, Innovation Pharma is actively exploring developing Brilacidin-OM as a sachet—an industry term for a small packet, similar to a common sugar packet. A sachet is easily transported and is less expensive than a liquid formulation and should be considerably less costly than a sterile IV drug for SOM. Add in the facility costs of multiple IV infusions per week over a treatment period of 6-7 weeks, and the cost can easily escalate (e.g. 1 hour of infusion, 5 days a week), which can severely limits a drug’s commercial prospects, especially if there are far less expensive alternatives. With a sachet, the Company envisions patients simply mixing the contents of the Brilacidin-OM sachet with water for a quick-and-easy treatment at home or on-the-go for the prevention of SOM.¨

I was going to go on and make a 1/2 a**ed joke about why, when in contention of crossing the finish line first or second while approaching the finish line during the Boston Marathon, would a runner suddenly change change course to buy I new pair of sneakers(b4 crossing) at Bill Rodgers running store in near by Fanuel Hall Marketplace with the runner thinking- hey I can run faster next year with a better pair of sneakers?
https://en.wikipedia.org/wiki/Bill_Rodgers_(runner)

But, while cutting and pasteing the above top paragraph, I was reminded of a response to a post of mine, from a well respected poster, who pointed out the referenced issues noted in it w/o referencing it. So, I now believe they are approaching the fda with two prongs, spit and rinse formulation(results in hand, and sachet formulation(Evonik assistance, also known and respected by FDA), and will meet with fda with info from the second formulation in hand. Could explain the recent Aspire deal(suggested by Hogan Lovells?)

Recent pr included Evonik, and recent otc filing(thx again HereToday) referenced Hogan Lovells. Neither are lightweights.

I am still a frustrated long, but think LE is now more Jed than Jethro.

We shall see.


.